Human Pharmacology of the methamphetamine stereoisomers

To help predict the consequences of precursor regulation, we compared the pharmacokinetics and pharmacodynamics of the methamphetamine (INN, metamfetamine) stereoisomers.

[1]  A. Beckett,et al.  The effect of N‐alkyl chain length and stereochemistry on the absorption, metabolism and urinary excretion of N‐alkylamphetamines in man * , 1973, The Journal of pharmacy and pharmacology.

[2]  A. Jeffcoat,et al.  Clinical effects of methamphetamine vapor inhalation. , 1991, Life sciences.

[3]  F. Vollenweider,et al.  The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers , 2000, Journal of psychopharmacology.

[4]  D. Mckenna,et al.  3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine , 1991, Pharmacology Biochemistry and Behavior.

[5]  F. Vollenweider,et al.  Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans , 2000, Neuropsychopharmacology.

[6]  J. Mendelson,et al.  Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans , 2002, Psychopharmacology.

[7]  B. Sadler,et al.  Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[8]  Reese T. Jones,et al.  The bioavailability of intranasal and smoked methamphetamine , 2003, Clinical pharmacology and therapeutics.

[9]  B. Sadler,et al.  Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[10]  R. E. Hicks,et al.  Clinical effects of daily methamphetamine administration. , 1991, Clinical neuropharmacology.

[11]  Suneel K. Gupta,et al.  Dose‐Proportional and Stereospecific Pharmacokinetics of Methylphenidate Delivered Using an Osmotic, Controlled‐Release Oral Delivery System , 2000, Journal of clinical pharmacology.

[12]  G. W. Moore,et al.  Determination of therapeutic blood levels of methamphetamine and pentobarbital by GC. , 1971, Journal of pharmaceutical sciences.

[13]  R. Watson,et al.  Heart disease, methamphetamine and AIDS. , 2003, Life sciences.

[14]  W Melega,et al.  Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  R. Rothman,et al.  Monoamine transporters and psychostimulant drugs. , 2003, European journal of pharmacology.

[16]  K. Rice,et al.  Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin , 2001, Synapse.

[17]  I. Creese.  Stimulants, neurochemical, behavioral, and clinical perspectives , 1983 .

[18]  F. Castellanos,et al.  Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core , 2005, Psychopharmacology.

[19]  A. Poklis,et al.  alpha-benzyl-N-methylphenethylamine (BNMPA), an impurity of illicit methamphetamine synthesis: III. Detection of BNMPA and metabolites in urine of methamphetamine users. , 1996, Journal of analytical toxicology.

[20]  D. Segal,et al.  Amphetamine and its analogs : psychopharmacology, toxicology, and abuse , 1994 .

[21]  Donald F. Smith.  CRC handbook of stereoisomers : drugs in psychopharmacology , 1984 .

[22]  T. Vree.  Pharmacokinetics and metabolism of amphetamines , 1973 .

[23]  Lon-Mu Liu,et al.  Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. , 2003, Addiction.

[24]  D. F. Neri,et al.  Chronopharmacokinetics and Chronopharmacodynamics of Dextromethamphetamine in Man , 1996, Journal of clinical pharmacology.

[25]  C. Spielberger,et al.  Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire" , 1983 .

[26]  O. Wolkowitz,et al.  Altering Cortisol Level does not Change the Pleasurable Effects of Methamphetamine in Humans , 2003, Neuropsychopharmacology.

[27]  E. Änggård,et al.  Pharmacokinetic studies with amphetamines-relationship to neuropsychiatric disorders , 1973, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  A. Beckett,et al.  The amphetamines: clinical and pharmacokinetic implications of recent studies of an assay procedure and urinary excretion in man. , 1966, Arzneimittel-Forschung.

[29]  G. Koob.  Drugs of abuse: anatomy, pharmacology and function of reward pathways. , 1992, Trends in pharmacological sciences.

[30]  Reese T. Jones,et al.  Methamphetamine and ethanol interactions in humans , 1995, Clinical pharmacology and therapeutics.

[31]  B. Logan,et al.  Methamphetamine - Effects on Human Performance and Behavior. , 2002, Forensic science review.

[32]  Frank T Peters,et al.  Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. , 2002, Clinical chemistry.

[33]  M. Huestis,et al.  Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. , 2003, Clinical chemistry.

[34]  M. Mayersohn,et al.  Influence of activated charcoal on the disposition kinetics of methamphetamine enantiomers in the rat following intravenous dosing. , 1996, Journal of pharmaceutical sciences.

[35]  A. Kurosu,et al.  Interpretation and enantiomer analysis of methamphetamine abusers' urine and illegally brewed methamphetamine crystals. , 2000, Journal of analytical toxicology.

[36]  A. Buss,et al.  An inventory for assessing different kinds of hostility. , 1957, Journal of consulting psychology.

[37]  W. Gentry,et al.  Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. , 2000, The Journal of pharmacology and experimental therapeutics.

[38]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.